Does Rallies show Form 4 insider transactions for ELVN?

Yes. Rallies tracks ELVN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ELVN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ELVN. It does not provide personalized investment advice.

ELVN (Enliven Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Enliven Therapeutics, Inc. Common Stock (ELVN) is a publicly traded Healthcare sector company. As of May 20, 2026, ELVN trades at $41.87 with a market cap of $2.41B and a P/E ratio of -22.91. ELVN moved +4.27% today. Year to date, ELVN is +175.21%; over the trailing twelve months it is +140.85%. Its 52-week range spans $13.30 to $48.53. Analyst consensus is strong buy with an average price target of $57.14. Rallies surfaces ELVN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ELVN stock inside the company?

Recent ELVN insider activity includes Collins Helen Louise sold 140, Collins Helen Louise sold 2.42K, Collins Helen Louise sold 2.44K, Collins Helen Louise sold 40.00K, and Collins Helen Louise sold 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ELVN Key Metrics

Key financial metrics for ELVN
Metric	Value
Price	$41.87
Market Cap	$2.41B
P/E Ratio	-22.91
EPS	$-1.83
Dividend Yield	0.00%
52-Week High	$48.53
52-Week Low	$13.30
Volume	567.19K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-103.69M
Gross Margin	0.00%

Recent ELVN Insider Trades

Collins Helen Louise sold 140 (~$6.41K) on Apr 17, 2026.
Collins Helen Louise sold 2.42K (~$114.64K) on Apr 17, 2026.
Collins Helen Louise sold 2.44K (~$117.30K) on Apr 17, 2026.
Collins Helen Louise sold 40.00K (~$1.40M) on Mar 25, 2026.
Collins Helen Louise sold 5.00K (~$138.80K) on Mar 17, 2026.

Latest ELVN News

Enliven reports Q1 net loss, $452M runway and H2 2026 Phase 3 start — May 7, 2026
Enliven's ELVN-001 Yields 69% MMR Rate in 60-Patient Phase 1b Trial, Phase 3 Set for H2 2026 — Jan 8, 2026

ELVN Analyst Consensus

8 analysts cover ELVN: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $57.14.

Common questions about ELVN

Who is trading ELVN stock inside the company?: Recent ELVN insider activity includes Collins Helen Louise sold 140, Collins Helen Louise sold 2.42K, Collins Helen Louise sold 2.44K, Collins Helen Louise sold 40.00K, and Collins Helen Louise sold 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ELVN?: Yes. Rallies tracks ELVN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ELVN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ELVN. It does not provide personalized investment advice.